OLIC is poised to leverage its over four decades of expertise in pharmaceutical and healthcare product manufacturing to become a leader in women's healthcare. The company is expanding its business into women's health with high quality pharmaceutical products, including an innovative natural estrogen in combined oral contraceptive, while also working to raise awareness about women's health. This includes promoting knowledge, access to accurate health information, and the proper use of medication - empowering women to make informed decisions and take an active role in their own healthcare for a better and more sustainable quality of life.
OLIC (Thailand) Limited, headquartered in Bang Pa-in Industrial Estate, Bang Pa-in District, Phra Nakhon Si Ayutthaya Province, with an additional office in Mitrtown Office Tower, Bangkok, is a subsidiary of Fuji Pharma Co., Ltd., based in Tokyo, Japan. Fuji Pharma Co., Ltd. is a leading medical company specializing in the research and development of pharmaceuticals and healthcare products for women, providing a strong foundation for OLIC's business and operations.
Mr. Yoshihiro Takada, Managing Director of OLIC (Thailand) Limited, said,"For over 40 years, OLIC has operated in Thailand as the largest full-service contract development and manufacturing organization (CDMO) in Southeast Asia, gaining the trust of over 30 leading pharmaceutical companies worldwide through our manufacturing expertise which spans product development and improvement, analytical method validation, production and packaging, storage and delivery, and product registration - all adhering to international quality and manufacturing standards. Today, OLIC is ready to become a leader in women's healthcare by providing high quality pharmaceutical products, including natural estrogen in combined oral contraceptive, endometriosis medication, short-term acute post-operative pain management treatment and hormone replacement therapy, both in Thailand and across ASEAN countries. We are also committed to enhancing knowledge, understanding, and access to accurate health information to deliver the best health and well-being for women."
Understanding the Market - Accessing Women's Healthcare
According to data from Research and Markets.com, the global women's healthcare market is experiencing significant growth and is projected to reach a value of USD 66 billion by 2033.[1] The largest segment of this market relates to gynecological disorders - conditions that affect the normal function of the female reproductive system.
This growth is a result of increasing awareness about women's health issues, driven by a range of factors,[2] such as rising healthcare expenditures, advancements in medical technology, and a greater focus on preventive care. There is a growing demand for products and services addressing women's unique health needs, including reproductive health, maternal health, breast health, menopause management, and sexual health.
In Southeast Asia, the contraceptive market is valued at 6 billion baht,[3] with Thailand holding a 50% market share. Data from the Ministry of Public Health's Health Data Center (2023)[4] indicates that Thai women have a higher disease prevalence rate than men, with 17 million women affected compared to 11 million men. Common women's health conditions include breast cancer, cervical cancer, and complications related to fetal development and the amniotic sac.
OLIC anticipates continued expansion in the women's healthcare market, presenting opportunities for healthcare innovations. The company remains committed to continuously studying and understanding women's health issues to provide innovative solutions that align with current healthcare needs and trends.
Natural Estrogen in Combined Oral Contraceptive - an Innovative Healthcare Solution for Today's Women
Mr. Pannavich Chitmetheepong, B.Sc. in Pharm, MBA, Pharma Business Unit Director of OLIC (Thailand) Limited, said, "OLIC recently launched an innovative natural estrogen in combined oral contraceptive that exhibits selective actions and improved safety profile, providing a new option for women in Thailand facing health issue. The pharmaceutical product is now available at healthcare facilities and leading pharmacies nationwide.
Furthermore, on the occasion of International Women's Day, OLIC is organizing activities to raise awareness about women's health, promoting knowledge, access to accurate and reliable health information, and the appropriate use of medications. This initiative enables women to make informed decisions and take an active role in their healthcare through continuous educational content and engagement activities under the 'Be with HER' - Empowering Her Health Decisions campaign, which includes the creation of online communication channels featuring short educational videos, along with year-round activities in collaboration with healthcare partners."
Raising awareness about women's health is a key focus of OLIC's business operations. The company remains committed to ongoing research and the development of innovative solutions to meet the evolving health needs of women. OLIC aims to be a true healthcare partner, not only for women but also academic organizations, healthcare professionals, hospitals, clinics, pharmacies, and stakeholders throughout the supply chain - working together to enhance women's quality of life.
[1] Fuji Pharma Co., Ltd. (2024). Expansion of the Women's Healthcare Market. New Mid-Term Business Plan FY9/2025-FY9/2029, 19.
[2] Research and Markets. (2024). Women's Health Market Report 2024-2034. https://www.researchandmarkets.com/reports/5806065/womens-health-market-report
[3] Fuji Pharma Co., Ltd. (2025). Notice of the launch of E4/DRSP in drugstores by OLIC (Thailand) Limited.
[4] Health Data Center: HDC Ministry of Public Health. (2023). as cited in the Ministry of Social Development and Human Security. (2024). Women and Health, 3.
Source: ABM Connect